PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8748111

Therapeutics 1995.

M Pirmohamed·U Martin
View original source ↗Export metadata ↓

Abstract

A joint conference on therapeutics with the Faculty of Pharmaceutical Medicine was held at the Royal College of Physicians on 28 June 1995, organised by Professor M C L'E Orme. A wide variety of topics was covered ranging from management of acute poisoning to the treatment of myocardial infarction, as well as the teaching of therapeutics in the new undergraduate medical curriculum. The aim of the conference was to provide an overview of the most recent therapeutic developments and controversies in the specific subject areas covered.

Explore related subjects

Bone Diseases, MetabolicDrug TherapyHumansIllicit DrugsMyocardial InfarctionPeptic UlcerPoisoningSocieties, MedicalSubstance-Related DisordersUnited KingdomConference Proceedings

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Pirmohamed, U Martin. Therapeutics 1995.. https://pubmed.ncbi.nlm.nih.gov/8748111/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Chronic kidney disease-mineral-bone disorder: a new paradigm.

Disturbances in mineral and bone metabolism are prevalent in chronic kidney disease (CKD) and an important cause of morbidity, decreased quality of life, and extraskeletal calcification that have been associated with increased cardiovascular mortality. These disturbances have traditionally been termed renal osteodystrophy and classified on the basis of bone biopsy. Kidney Disease: Improving Global Outcomes (KDIGO) recently sponsored a Controversies Conference to evaluate this definition. The recommendations were that (1) the term renal osteodystrophy be used exclusively to define alterations in bone morphology associated with CKD and (2) the term CKD-mineral and bone disorder (CKD-MBD) be used to describe the broader clinical syndrome that develops as a systemic disorder of mineral and bone metabolism as a result of CKD. CKD-MBD is manifested by an abnormality of any one or a combination of the following: laboratory-abnormalities of calcium, phosphorus, PTH, or vitamin D metabolism; bone-changes in bone turnover, mineralization, volume, linear growth, or strength; and calcification-vascular or other soft-tissue calcification. The pathogenesis and clinical manifestations of these components of CKD-MBD are described in detail in this issue of Advances in Chronic Kidney Disease.

Bone Diseases, Metabolic↗